Niagen Bioscience, Inc. (NAGE) — SEC Filings
Niagen Bioscience, Inc. (NAGE) — 26 SEC filings. Latest: 8-K (Dec 22, 2025). Includes 15 8-K, 6 10-Q, 2 DEF 14A.
View Niagen Bioscience, Inc. on SEC EDGAR
Overview
Niagen Bioscience, Inc. (NAGE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 22, 2025: On December 18, 2025, Niagen Bioscience, Inc. (formerly ChromaDex Corp.) entered into a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in
Sentiment Summary
Across 26 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 23 neutral, 1 mixed. The dominant filing sentiment for Niagen Bioscience, Inc. is neutral.
Filing Type Overview
Niagen Bioscience, Inc. (NAGE) has filed 15 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13D/A with the SEC between Mar 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (26)
Risk Profile
Risk Assessment: Of NAGE's 24 recent filings, 1 were flagged as high-risk, 15 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $95.584M |
| Net Income | $13.250M |
| EPS | $0.17 |
| Debt-to-Equity | 0.39 |
| Cash Position | $64.290M |
| Operating Margin | 12.76% |
| Total Assets | $98.139M |
| Total Debt | $27.463M |
Key Executives
- Dr. Robert L. Smith
- Ms. Jennifer L. Grant
- Mr. Michael J. Newman
- Ms. Laura L. Chen
- Dr. Robert H. Eckman
- Ms. Sarah E. McSweeney
- LI KA SHING
- Ms. Sarah E. Johnson
- Mr. Jonathan B. Webb
- Dr. Robert Griffin
- Ms. Sarah McSweeney
Industry Context
The health and wellness supplement industry, particularly focusing on cellular health and aging, is experiencing significant growth driven by increasing consumer awareness of preventative health measures. Companies like Niagen Bioscience are positioned to capitalize on this trend with products like NAD+ precursors. However, the market is competitive, with a constant need for scientific validation and differentiation.
Top Tags
10-Q (4) · material-agreement (3) · SEC Filing (3) · financials (3) · board-of-directors (3) · corporate-action (2) · Biotechnology (2) · 8-K (2) · corporate-governance (2) · 10-K (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 001-37752 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 26-2940963 | Company's tax identification number. |
| Net Sales (Nine Months) | $95.584M | Increased 35.6% from $70.472 million in 2024 |
| Net Sales (Three Months) | $33.986M | Increased 32.8% from $25.580 million in 2024 |
| Net Income (Nine Months) | $13.250M | Increased from $1.371 million in 2024 |
| Net Income (Three Months) | $4.578M | Increased from $1.878 million in 2024 |
| Gross Profit (Nine Months) | $61.485M | Increased from $43.389 million in 2024 |
| Operating Income (Nine Months) | $12.193M | Increased from $615 thousand in 2024 |
| Cash and Cash Equivalents | $64.290M | As of September 30, 2025, up from $44.660 million at December 31, 2024 |
| Net Cash Provided by Operating Activities | $12.825M | For the nine months ended September 30, 2025 |
| Basic EPS (Nine Months) | $0.17 | Increased from $0.02 in 2024 |
| Shares Outstanding | 79,806,139 | As of November 3, 2025 |
| Common Stock | $0.00 | Consistent across all reported periods, indicating no change in common stock value. |
| Additional Paid-In Capital | $0.00 | Consistent across all reported periods, showing no new capital contributions. |
| Retained Earnings | $0.00 | Consistent across all reported periods, indicating no accumulated profits or losses. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Niagen Bioscience, Inc. (NAGE)?
Niagen Bioscience, Inc. has 26 recent SEC filings from Mar 2024 to Dec 2025, including 15 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of NAGE filings?
Across 26 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 23 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Niagen Bioscience, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Niagen Bioscience, Inc. (NAGE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Niagen Bioscience, Inc.?
Key financial highlights from Niagen Bioscience, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for NAGE?
The investment thesis for NAGE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Niagen Bioscience, Inc.?
Key executives identified across Niagen Bioscience, Inc.'s filings include Dr. Robert L. Smith, Ms. Jennifer L. Grant, Mr. Michael J. Newman, Ms. Laura L. Chen, Dr. Robert H. Eckman and 6 others.
What are the main risk factors for Niagen Bioscience, Inc. stock?
Of NAGE's 24 assessed filings, 1 were flagged high-risk, 15 medium-risk, and 8 low-risk.
What are recent predictions and forward guidance from Niagen Bioscience, Inc.?
Forward guidance and predictions for Niagen Bioscience, Inc. are extracted from SEC filings as they are enriched.